Last year, 12 patients in the Supportive Care Clinic at VCU Massey Cancer Center stepped inside a conference room, donned motion sensors and engaged in a facilitated life review, acting out various parts of their lives through a virtual avatar displayed on a projection screen. Recently, the unique collaboration between researchers at VCUarts and Massey’s Palliative Care Program was recognized with a tie for first place in the 2nd Annual Hamilton International Arts in Health Awards from the National Organization for Arts in Health (NOAH).
VCU Massey Cancer Center and Riverside Health System collaborate to expand access to cancer clinical trials throughout coastal Virginia
Cancer patients living in coastal Virginia have greater access to cutting-edge clinical trials now that Riverside Health System has joined Virginia Commonwealth University Massey Cancer Center’s Clinical Research Affiliate Network. This collaboration will bring National Cancer Institute (NCI)-sponsored clinical trials testing promising new cancer treatments to seven Riverside locations, including Peninsula Cancer Institute locations in Newport News, Williamsburg and Gloucester; Cancer Specialists of Tidewater locations in Virginia Beach, Chesapeake and Suffolk; and Riverside Shore Cancer Center in Onancock.
A team of scientists led by Paul Dent, Ph.D., at Virginia Commonwealth University Massey Cancer Center has discovered that an experimental cancer drug called AR-12 inhibits the SARS-CoV-2 virus, the cause of the COVID-19 pandemic, from infecting cells and replicating. Their findings were published online today in the journal Biochemical Pharmacology, and steps are now being taken to develop a clinical trial testing the novel oral treatment at VCU Health.
A stage 2 clinical trial testing the use of immunotherapy after surgery to reduce melanoma recurrence is currently underway at VCU Massey Cancer Center. Led by Andrew Poklepovic, M.D., the trial is eligible to any adult melanoma who is about to or recently underwent surgery and has no evidence of metastatic disease.
Massey researchers first to show that a specific protein inhibitor successfully kills multiple myeloma tumor cells
Cyclin-dependent kinase inhibitor 7 (CDK7) is a protein that regulates cell cycle progression. However, it also plays a key role in controlling transcription of three genes that help tumor cells proliferate and survive in patients with multiple myeloma, a form of plasma cell cancer.